Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?

NCT00363181 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00363181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00363181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?
Lead sponsor
Stanford University
Phase
Observational
Overall status
Completed
Start date
April 30, 2006
Completion date
December 31, 2011
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insulin resistance, metabolic syndrome x, mood disorders, psychotic disorders, schizophrenia and disorders with psychotic features